全文获取类型
收费全文 | 2037929篇 |
免费 | 151623篇 |
国内免费 | 13048篇 |
专业分类
耳鼻咽喉 | 25148篇 |
儿科学 | 62810篇 |
妇产科学 | 51515篇 |
基础医学 | 286848篇 |
口腔科学 | 55179篇 |
临床医学 | 189488篇 |
内科学 | 395536篇 |
皮肤病学 | 42973篇 |
神经病学 | 157773篇 |
特种医学 | 75470篇 |
外国民族医学 | 318篇 |
外科学 | 301417篇 |
综合类 | 65086篇 |
现状与发展 | 33篇 |
一般理论 | 836篇 |
预防医学 | 152626篇 |
眼科学 | 48841篇 |
药学 | 153088篇 |
135篇 | |
中国医学 | 12549篇 |
肿瘤学 | 124931篇 |
出版年
2021年 | 24262篇 |
2020年 | 15861篇 |
2019年 | 22312篇 |
2018年 | 29483篇 |
2017年 | 23167篇 |
2016年 | 24722篇 |
2015年 | 29736篇 |
2014年 | 40661篇 |
2013年 | 55015篇 |
2012年 | 77519篇 |
2011年 | 81682篇 |
2010年 | 49111篇 |
2009年 | 44627篇 |
2008年 | 72469篇 |
2007年 | 76577篇 |
2006年 | 76253篇 |
2005年 | 72889篇 |
2004年 | 68869篇 |
2003年 | 65345篇 |
2002年 | 62073篇 |
2001年 | 96465篇 |
2000年 | 97368篇 |
1999年 | 81142篇 |
1998年 | 23836篇 |
1997年 | 21079篇 |
1996年 | 20334篇 |
1995年 | 19615篇 |
1994年 | 17759篇 |
1993年 | 16050篇 |
1992年 | 59168篇 |
1991年 | 56904篇 |
1990年 | 54382篇 |
1989年 | 52110篇 |
1988年 | 47424篇 |
1987年 | 46151篇 |
1986年 | 43437篇 |
1985年 | 41131篇 |
1984年 | 30677篇 |
1983年 | 26064篇 |
1982年 | 15262篇 |
1979年 | 26273篇 |
1978年 | 18356篇 |
1977年 | 15581篇 |
1976年 | 14513篇 |
1975年 | 15063篇 |
1974年 | 18141篇 |
1973年 | 17374篇 |
1972年 | 16055篇 |
1971年 | 14782篇 |
1970年 | 13716篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
51.
52.
53.
P E Santos E Piontelli Y R Shea M L Galluzzo S M Holland M E Zelazko S D Rosenzweig 《Medical mycology》2006,44(8):749-753
Infections due to Penicillium species other than P.marneffei are rare. We identified a boy with X-linked chronic granulomatous disease (X-CGD) with a pulmonary nodule and adjacent rib osteomyelitis caused by Penicillium piceum. The only sign of infection was an elevated sedimentation rate. P. piceum was isolated by fine needle aspirate and from excised infected tissues. Surgical removal and one year of voriconazole treatment were very well tolerated and led to complete recovery. Microbiological, microscopic and molecular studies support the fungal diagnosis. P. piceum should be considered as a relevant pathogen in immunocompromised patients. 相似文献
54.
55.
56.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
57.
58.
59.
60.
H J Kim C H Kang Y T Kim S-W Sung J H Kim S M Lee C-G Yoo C-T Lee Y W Kim S K Han Y-S Shim J-J Yim 《The European respiratory journal》2006,28(3):576-580
Although surgical lung resection could improve prognosis in some patients with multidrug-resistant tuberculosis (MDR-TB), there are no reports on the optimal candidates for this surgery. The aim of the present study was to elucidate the prognostic factors for surgery in patients with MDR-TB. Patients who underwent lung resection for the treatment of MDR-TB between March 1993 and December 2004 were included in the present study. Treatment failure was defined as greater than or equal to two of the five cultures recorded in the final 12 months of treatment being positive, any one of the final three cultures being positive, or the patient having died during treatment. The variables that affected treatment outcomes were identified through univariate and multivariate logistic regression analysis. In total, 79 patients with MDR-TB were included in the present study. The treatment outcomes of 22 (27.8%) patients were classified as failure. A body mass index <18.5 kg x m(-2), primary resistance, resistance to ofloxacin and the presence of a cavitary lesion beyond the range of the surgical resection were associated with treatment failure. Low body mass index, primary resistance, resistance to ofloxacin and cavitary lesions beyond the range of resection are possible poor prognostic factors for surgical lung resection in multidrug-resistant tuberculosis patients. 相似文献